Orlistat Induces Ferroptosis in Pancreatic Neuroendocrine Tumors by Inactivating the MAPK Pathway

Background: Orlistat is an antiobesity drug approved by the US Food and Drug Administration (FDA) with potential antitumor activity against a few malignant tumors, however, whether orlistat affects the progression of pancreatic neuroendocrine tumors (pNETs) remains unknown. Methods: Protein and mRNA...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Mujie, Lu, Feiyu, Chen, Jinhao, Yu, Ping, Xu, Yanling, He, Na, Hu, Chunhua, Zhong, Yuan, Yan, Lijun, Gu, Danyang, Xu, Lin, Bai, Jianan, Tian, Ye, Tang, Qiyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240670/
https://www.ncbi.nlm.nih.gov/pubmed/37283794
http://dx.doi.org/10.7150/jca.83118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240670/
https://www.ncbi.nlm.nih.gov/pubmed/37283794
http://dx.doi.org/10.7150/jca.83118

Ejemplares similares